Paradigm Health Acquires Flatiron Health's Oncology Research Unit, Fueled by $78M and AI, to Revolutionize Clinical Trials Access
- 2 days ago
- 3 min read
The landscape of clinical cancer research is undergoing a dramatic transformation following the December 4, 2025, announcement that Paradigm Health has acquired the Clinical Research Business of Flatiron Health. This major transaction, which includes Flatiron’s comprehensive tech-enabled U.S. oncology research network, has been paired with an oversubscribed $78 million Series B funding round. The financing was led by ARCH Venture Partners and supported by various leading healthcare and life sciences investors. Together, the acquisition and funding position Paradigm Health to fulfill its mission of rebuilding the clinical research ecosystem.
The synergy between the two organizations creates the largest oncology research network in the United States. Through this merger, Paradigm Health expands its reach to include more than 25 academic medical centers and health systems, as well as access to nearly 100 community oncology practices nationwide, collectively reaching over 2.4 million patients across the U.S.. The company's platform now encompasses 166 healthcare provider organizations across 45 U.S. states, ensuring that 70% of the U.S. cancer population is within easy reach of a clinical trial site.
A cornerstone of this strategic collaboration is the deep integration of artificial intelligence. The partnership includes a multi-year effort to integrate AI for improved patient matching and trial access across U.S. providers. Kent Thoelke, Paradigm Health CEO, stated that combining Paradigm Health's AI-powered platform with Flatiron’s proven infrastructure is a significant step toward accelerating their impact so that more trials can happen where patients receive routine care. The long-term partnership involves natively integrating Paradigm Health’s solutions into Flatiron’s OncoEMR®, an industry-leading electronic health record used by over 4,500 providers in community oncology.
This combined AI infrastructure is already delivering results, enabling the automation of patient matching and site feasibility, which has helped health systems accrue to clinical trials four times faster. Furthermore, Paradigm Health aims to expand U.S. research capacity and bring trials directly to American communities without demanding costly new infrastructure from providers.
A primary driver behind the unified strategy is addressing the critical issue of patient representation. Currently, clinical trials often fail to reflect the diverse populations that new therapies are meant to serve, with patients in community and rural settings having limited access. By creating a scalable trial ecosystem embedded directly into real-world clinical workflows, Paradigm Health seeks to democratize access to cutting-edge therapies. Nathan Hubbard, Flatiron Health CEO, noted that the combination of strengths is building a stronger, more connected ecosystem to advance the shared mission of bringing new treatments to patients faster.
The acquisition also strengthens relationships with the biopharma sector, allowing Paradigm Health to serve 15 of the top 20 global biopharma companies. This increased capacity supports running pragmatically designed Phase IV clinical trials embedded into routine care, thereby speeding up post-market approval evidence generation. The overall effort is designed to make research a seamless part of patient care in every community, enhancing efficiency and accessibility worldwide.
The expansion of the Oncology Research network, powered by AI and substantial investment, is like turning fragmented dirt roads into a unified digital highway: accelerating the journey of new treatments from the lab directly into community clinics for the benefit of a more representative patient population.
🔖 Sources
Keywords: Paradigm Health
Paradigm Health
Comments